GlassScriptPhysician profile
Amanda M Evans
NPI 1245890615
$1,872.22
in general payments reported to CMS, 2019-2025
25 companies · $670 in 2025
The $670 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $37.99 · 2022: $227 · 2023: $619 · 2024: $318 · 2025: $670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,570 · Education: $37.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,569.53 |
| Education | $37.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $272.93 | 2022-2025 | Mounjaro, Jardiance, Emgality |
| Abbvie INC. | $222.13 | 2024-2025 | |
| Novo Nordisk INC | $206.57 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $161.33 | 2022-2025 | Trelegy Ellipta, Shingrix, Bexsero |
| Astellas Pharma US INC | $130.87 | 2023-2024 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $100.50 | 2023-2025 | Xifaxan |
| Dynavax Technologies Corporation | $93.94 | 2024-2025 | Heplisav-B |
| Amgen INC. | $83.56 | 2023-2025 | Otezla, Repatha, Otezla |
| Sumitomo Pharma America, INC. | $82.57 | 2023 | Gemtesa |
| Exact Sciences Corporation | $75.47 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Corium, LLC | $60.70 | 2022-2023 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $50.46 | 2023-2025 | Rexulti |
| Pfizer INC. | $48.92 | 2024-2025 | |
| Axsome Therapeutics, INC. | $47.97 | 2025 | Auvelity |
| Gilead Sciences, INC. | $37.26 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $30.48 | 2025 | Saphnelo, Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $24.41 | 2021 | |
| Sunovion Pharmaceuticals INC. | $22.01 | 2022 | |
| Dexcom, INC. | $21.61 | 2025 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.55 | 2025 | Caplyta |
| Tris Pharma INC | $17.61 | 2022 | |
| Lucid Diagnostics INC. | $16.73 | 2022 | |
| Esperion Therapeutics, INC. | $16.22 | 2024 | Nexletol |
| Novartis Pharmaceuticals Corporation | $13.84 | 2023 | |
| Daiichi Sankyo INC. | $13.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.